# FINANCIERE DE TUBIZE

Summary updated: 2026-10-04T15:06:47.526577Z
Canonical: https://finbar.com/research/companies/financiere-de-tubize

## Overview

Financière de Tubize is a Belgian mono-holding company whose sole investment is UCB; it has no commercial or industrial operations of its own [1](https://app.finbar.com/go?id=P116594653). At 31 December 2025, it held 36.28% of UCB’s issued shares and reported total assets of €1.934 billion [2](https://app.finbar.com/go?id=P8269019). Tubize’s role is to act as UCB’s long-term reference shareholder, contributing to its strategy and supporting stability for long-term investment [3](https://app.finbar.com/go?id=P107163778)[4](https://app.finbar.com/go?id=P5594306).

UCB, rather than Tubize, is the operating biopharmaceutical company, focused on immunology and neurology, with a presence in nearly 40 countries [5](https://app.finbar.com/go?id=P25111795)[6](https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf). Tubize’s stated purpose includes generating long-term shareholder returns, supporting UCB’s development of treatments for serious illnesses, and fostering a sustainable biopharma ecosystem [7](https://app.finbar.com/go?id=P79952569)[8](https://app.finbar.com/go?id=P10005445). Tubize reported no employees; for operating scale, UCB reported 2025 revenue of €7.741 billion and 10,117 employees [9](https://app.finbar.com/go?id=P36293766)[6](https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf).
[1](https://app.finbar.com/go?id=P116594653)[2](https://app.finbar.com/go?id=P8269019)[3](https://app.finbar.com/go?id=P107163778)[4](https://app.finbar.com/go?id=P5594306)[5](https://app.finbar.com/go?id=P25111795)[6](https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf)[7](https://app.finbar.com/go?id=P79952569)[8](https://app.finbar.com/go?id=P10005445)[9](https://app.finbar.com/go?id=P36293766)[6](https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf)

## Products & services

Financière de Tubize does not itself market products or provide commercial services: it is a mono-holding company with no commercial or industrial activity, and its sole investment is UCB [1](https://app.finbar.com/go?id=P116594653). Its role is as a long-term shareholder; at 31 December 2025 it held 36.28% of UCB’s issued shares [10](https://app.finbar.com/go?id=P18866393).

The medicines associated with Tubize are products of its investee UCB, not of Tubize. Products named in Tubize’s 2025 reporting include BIMZELX, FINTEPLA, RYSTIGGO and ZILBRYSQ [11](https://app.finbar.com/go?id=P80337790). UCB describes BIMZELX (bimekizumab) as an IL‑17A and IL‑17F inhibitor [12](https://www.ucb.com/solutions/products/bimzelx); FINTEPLA (fenfluramine) is used for seizures associated with Dravet and Lennox–Gastaut syndromes [13](https://www.ucb.com/solutions/products/fintepla); and RYSTIGGO (rozanolixizumab) and ZILBRYSQ (zilucoplan) are treatments for generalized myasthenia gravis [14](https://www.ucb.com/solutions/products/rystiggo)[15](https://www.ucb.com/solutions/products/zilbrysq). No product-sales mix or product contribution to performance applies directly to Tubize, which has no product sales of its own.
[1](https://app.finbar.com/go?id=P116594653)[10](https://app.finbar.com/go?id=P18866393)[11](https://app.finbar.com/go?id=P80337790)[12](https://www.ucb.com/solutions/products/bimzelx)[13](https://www.ucb.com/solutions/products/fintepla)[14](https://www.ucb.com/solutions/products/rystiggo)[15](https://www.ucb.com/solutions/products/zilbrysq)[12](https://www.ucb.com/solutions/products/bimzelx)[13](https://www.ucb.com/solutions/products/fintepla)[14](https://www.ucb.com/solutions/products/rystiggo)[15](https://www.ucb.com/solutions/products/zilbrysq)

## Geographic presence

Financière de Tubize is a mono-holding company with no commercial or industrial activity; its geographic exposure is through its 36.28% holding in UCB at 31 December 2025, rather than a separately reported operating or sales footprint [1](https://app.finbar.com/go?id=P116594653)[10](https://app.finbar.com/go?id=P18866393).
[1](https://app.finbar.com/go?id=P116594653)[10](https://app.finbar.com/go?id=P18866393)

## Business segments

Financière de Tubize’s FY2025 reporting describes it as a holding company whose core focus is the long-term holding in UCB, an innovative global biopharmaceutical business. At 31 December 2025, Tubize held 36.28% of UCB’s issued shares. [3](https://app.finbar.com/go?id=P107163778)[5](https://app.finbar.com/go?id=P25111795)[10](https://app.finbar.com/go?id=P18866393)

Tubize does not report business segments or segment contribution percentages: it states that it is not required to prepare consolidated accounts, and its statutory company accounts do not provide an operating-segment breakdown. Accordingly, no segment percentages are disclosed. [16](https://app.finbar.com/go?id=P29783943)
[3](https://app.finbar.com/go?id=P107163778)[5](https://app.finbar.com/go?id=P25111795)[10](https://app.finbar.com/go?id=P18866393)[16](https://app.finbar.com/go?id=P29783943)[17](https://www.financiere-tubize.be/wp-content/uploads/2026/03/20260325-RA-2025-UK.pdf)

## Company history

Financière de Tubize dates to 1928. Company records describe Tubize as becoming part of the Janssen family that year; UCB was also created in 1928, as a separate milestone, by Emmanuel Janssen. [18](https://app.finbar.com/go?id=P55883835)[19](https://app.finbar.com/go?id=P108848728)[5](https://app.finbar.com/go?id=P25111795)

Tubize first became a UCB shareholder in 1961. It substantially increased its position in 1981 by acquiring half of Rhône-Poulenc’s UCB securities, while Royale Belge acquired the other half. After gradually taking over Royale Belge’s UCB shares, Tubize’s holding reached 40% in 2002. [20](https://app.finbar.com/go?id=P94793830)[21](https://app.finbar.com/go?id=P29482592)[22](https://app.finbar.com/go?id=P28775317)

In 2006, Tubize borrowed €100 million to participate in a UCB capital increase supporting UCB’s acquisition of Schwarz Pharma. On 25 April 2025, Bruno Holthof became chair of Tubize, succeeding Gaëtan Hannecart. [23](https://app.finbar.com/go?id=P107804037)[24](https://www.financiere-tubize.be/wp-content/uploads/2025/04/20250429-Communique-de-presse-nomination-BH-comme-president-CA-UK.pdf)
[18](https://app.finbar.com/go?id=P55883835)[19](https://app.finbar.com/go?id=P108848728)[5](https://app.finbar.com/go?id=P25111795)[20](https://app.finbar.com/go?id=P94793830)[21](https://app.finbar.com/go?id=P29482592)[22](https://app.finbar.com/go?id=P28775317)[23](https://app.finbar.com/go?id=P107804037)[24](https://www.financiere-tubize.be/wp-content/uploads/2025/04/20250429-Communique-de-presse-nomination-BH-comme-president-CA-UK.pdf)

## Sources

1. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p15](https://app.finbar.com/go?id=P116594653)
2. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p11](https://app.finbar.com/go?id=P8269019)
3. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4](https://app.finbar.com/go?id=P107163778)
4. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4](https://app.finbar.com/go?id=P5594306)
5. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4](https://app.finbar.com/go?id=P25111795)
6. [www.ucb.com](https://www.ucb.com/sites/default/files/2026-02/IAR_2025.pdf)
7. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4](https://app.finbar.com/go?id=P79952569)
8. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p4](https://app.finbar.com/go?id=P10005445)
9. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p25](https://app.finbar.com/go?id=P36293766)
10. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p16](https://app.finbar.com/go?id=P18866393)
11. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P80337790)
12. [www.ucb.com](https://www.ucb.com/solutions/products/bimzelx)
13. [www.ucb.com](https://www.ucb.com/solutions/products/fintepla)
14. [www.ucb.com](https://www.ucb.com/solutions/products/rystiggo)
15. [www.ucb.com](https://www.ucb.com/solutions/products/zilbrysq)
16. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p22](https://app.finbar.com/go?id=P29783943)
17. [www.financiere-tubize.be](https://www.financiere-tubize.be/wp-content/uploads/2026/03/20260325-RA-2025-UK.pdf)
18. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P55883835)
19. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P108848728)
20. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P94793830)
21. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P29482592)
22. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P28775317)
23. [FINANCIERE DE TUBIZE — Full financial report (2025 Y), p5](https://app.finbar.com/go?id=P107804037)
24. [www.financiere-tubize.be](https://www.financiere-tubize.be/wp-content/uploads/2025/04/20250429-Communique-de-presse-nomination-BH-comme-president-CA-UK.pdf)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.